Bioharvest Financials
This page shows Bioharvest (BHST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Bioharvest has an operating margin of -27.8%, meaning the company retains $-28 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -78.6% the prior year.
Bioharvest's revenue surged 98.8% year-over-year to $25.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Bioharvest's current ratio of 0.55 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 2/100, which could limit financial flexibility.
While Bioharvest generated -$6.7M in operating cash flow, capex of $2.8M consumed most of it, leaving -$9.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
For every $1 of reported earnings, Bioharvest generates $0.52 in operating cash flow (-$6.7M OCF vs -$12.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Bioharvest generated $25.2M in revenue in fiscal year 2024. This represents an increase of 98.8% from the prior year.
Bioharvest's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.1% from the prior year.
Bioharvest generated -$9.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 4.8% from the prior year.
Bioharvest reported -$12.9M in net income in fiscal year 2024. This represents a decrease of 2.8% from the prior year.
Bioharvest held $2.4M in cash against $0 in long-term debt as of fiscal year 2024.
Bioharvest had 17M shares outstanding in fiscal year 2024.
Bioharvest's gross margin was 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 10.9 percentage points from the prior year.
Bioharvest's operating margin was -27.8% in fiscal year 2024, reflecting core business profitability. This is up 50.9 percentage points from the prior year.
Bioharvest's net profit margin was -51.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 47.9 percentage points from the prior year.
Bioharvest invested $2.8M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 92.3% from the prior year.
BHST Income Statement
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Revenue | N/A | N/A |
| Cost of Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| R&D Expenses | N/A | N/A |
| SG&A Expenses | N/A | N/A |
| Operating Income | N/A | N/A |
| Interest Expense | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income | N/A | N/A |
| EPS (Diluted) | N/A | N/A |
BHST Balance Sheet
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Total Assets | N/A | N/A |
| Current Assets | $7.9M-13.2% | $9.1M |
| Cash & Equivalents | $2.4M-55.4% | $5.4M |
| Inventory | $3.7M+48.2% | $2.5M |
| Accounts Receivable | $1.1M+38.1% | $808K |
| Goodwill | N/A | N/A |
| Total Liabilities | N/A | N/A |
| Current Liabilities | $14.3M-46.1% | $26.5M |
| Long-Term Debt | N/A | N/A |
| Total Equity | $1.3M+109.0% | -$14.9M |
| Retained Earnings | -$96.4M-15.5% | -$83.5M |
BHST Cash Flow Statement
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | N/A | N/A |
| Dividends Paid | N/A | N/A |
| Share Buybacks | N/A | N/A |
BHST Financial Ratios
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Gross Margin | N/A | N/A |
| Operating Margin | N/A | N/A |
| Net Margin | N/A | N/A |
| Return on Equity | N/A | N/A |
| Return on Assets | N/A | N/A |
| Current Ratio | 0.55+0.2 | 0.34 |
| Debt-to-Equity | N/A | N/A |
| FCF Margin | N/A | N/A |
Note: The current ratio is below 1.0 (0.55), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Bioharvest's annual revenue?
Bioharvest (BHST) reported $25.2M in total revenue for fiscal year 2024. This represents a 98.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioharvest's revenue growing?
Bioharvest (BHST) revenue grew by 98.8% year-over-year, from $12.7M to $25.2M in fiscal year 2024.
Is Bioharvest profitable?
No, Bioharvest (BHST) reported a net income of -$12.9M in fiscal year 2024, with a net profit margin of -51.3%.
What is Bioharvest's EBITDA?
Bioharvest (BHST) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bioharvest's gross margin?
Bioharvest (BHST) had a gross margin of 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioharvest's operating margin?
Bioharvest (BHST) had an operating margin of -27.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Bioharvest's net profit margin?
Bioharvest (BHST) had a net profit margin of -51.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Bioharvest's free cash flow?
Bioharvest (BHST) generated -$9.5M in free cash flow during fiscal year 2024. This represents a 4.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioharvest's operating cash flow?
Bioharvest (BHST) generated -$6.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bioharvest's capital expenditures?
Bioharvest (BHST) invested $2.8M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does Bioharvest have outstanding?
Bioharvest (BHST) had 17M shares outstanding as of fiscal year 2024.
What is Bioharvest's current ratio?
Bioharvest (BHST) had a current ratio of 0.55 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioharvest's cash runway?
Based on fiscal year 2024 data, Bioharvest (BHST) had $2.4M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Bioharvest's earnings high quality?
Bioharvest (BHST) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioharvest?
Bioharvest (BHST) scores 26 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.